BridgeBio Pharma, Inc. (BBIO) Operating Margin
- Operating margin · 12 months: Value -69.81%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -69.81% | Operating income / revenue. Period ending 2026-06-30. $-497.80M ÷ $713.07M × 100 ≈ -69.81% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -497.80M USD | Operating Income (Loss) |
| Revenue | 713.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 505.38M USD | Research and Development Expense |
| Selling, general and administration | 645.86M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-497.80M | $713.07M | (m) | $505.38M | $645.86M | -69.81% |
| 2026-03-31 | $-525.00M | $579.96M | (m) | $467.16M | $588.76M | -90.52% |
| 2025-12-31 | $-523.41M | $502.08M | (m) | $451.95M | $531.23M | -104.25% |
| 2025-09-30 | $-609.88M | $353.78M | (m) | $465.89M | $467.92M | -172.39% |
| 2025-06-30 | $-656.43M | $235.81M | (m) | $473.46M | $399.12M | -278.37% |
| 2025-03-31 | $-697.69M | $127.42M | (m) | $476.92M | $329.49M | -547.57% |
| 2024-12-31 | $-592.97M | $221.90M | (m) | $506.46M | $288.93M | -267.22% |
| 2024-09-30 | $-544.36M | $217.76M | (m) | $506.34M | $241.73M | -249.98% |
| 2024-06-30 | $-510.30M | $219.12M | (m) | $511.03M | $208.69M | -232.88% |
| 2024-03-31 | $-480.86M | $218.60M | (m) | $503.82M | $185.29M | -219.98% |
| 2023-12-31 | $-607.37M | $9.30M | (m) | $455.71M | $150.59M | -6528.75% |
| 2023-09-30 | $-559.19M | $9.43M | (m) | $416.39M | $134.87M | -5931.12% |
| 2023-06-30 | $-530.61M | $5.67M | (m) | $383.76M | $130.28M | -9349.96% |
| 2023-03-31 | $-464.69M | $77.78M | (m) | $384.67M | $130.58M | -597.44% |
| 2022-12-31 | $-512.20M | $77.65M | (m) | $399.46M | $143.19M | -659.65% |
| 2022-09-30 | $-548.58M | $88.66M | (m) | $430.76M | $166.08M | -618.72% |
| 2022-06-30 | $-568.97M | $90.67M | (m) | $442.55M | $180.97M | -627.51% |
| 2022-03-31 | $-582.81M | $70.95M | (m) | $436.11M | $190.52M | -821.46% |
| 2021-12-31 | $-576.63M | $69.72M | $2.73M | $451.02M | $192.21M | -827.12% |
| 2021-09-30 | $-538.51M | $56.95M | (m) | $419.00M | (m) | -945.55% |
| 2021-06-30 | $-508.95M | $62.73M | (m) | $406.74M | (m) | -811.26% |
| 2021-03-31 | $-539.50M | (m) | (m) | $391.38M | (m) | (m) |
| 2020-12-31 | $-474.48M | $8.25M | (m) | $337.05M | (m) | -5751.99% |
| 2020-09-30 | $-425.63M | $21.95M | (m) | $304.36M | (m) | -1939.45% |
| 2020-06-30 | $-360.22M | (m) | (m) | $267.59M | (m) | (m) |
| 2020-03-31 | $-304.98M | (m) | (m) | $233.32M | (m) | (m) |
| 2019-12-31 | $-266.24M | $40.56M | (m) | $209.95M | (m) | -656.41% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-183.66M | (m) | (m) | $140.07M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-43.86M | (m) | (m) | $30.56M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |